ArticleInterdisciplinary cardiovascular and thoracic surgery2025
Rescue Therapy With Factor VII for Refractory Cardiac Surgical Bleeding: A Propensity-Score-Matched Study.
Article in Interdisciplinary cardiovascular and thoracic surgery, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
objectivesTo compare effectiveness and safety of rescue therapy approach with recombinant Factor VII activated (rFVIIa) for refractory bleeding in cardiac surgery compared with a propensity-score-matched control group at a single academic institution.
methodsIn total, 8860 adult patients had cardiac surgery with cardiopulmonary bypass between 2009 and 2019. Ninety-seven patients (1.1%) received rFVIIa; 81 (83.5%) of rFVIIa cases were propensity score matched 1:1 with controls using pre- and intraoperative variables. Effectiveness was assessed with coagulation tests, chest tube drainage, and reoperation for bleeding. Safety was assessed with morbi-mortality.
resultsThe median dose of rFVIIa was 55.6 μg/kg (IQR, 37.4-80.0 μg/kg). The first dose after CPB was given at a Median time of 176 min (IQR, 131-232 min). Postoperative INR was lower in the rFVIIa group (Median, 0.8; IQR, 0.7-0.9) versus control (Median, 1.4; IQR 1.3-1.6; P <.0001). Other coagulation tests, chest tube drainage, and reoperation for bleeding were no different. Mortality and thrombo-embolism were higher in the rFVIIa-OR, 3.17 (95% CI, 1.41-7.14; P = .0054) and OR, 10.50 (95% CI, 1.64-117.5; P = .0196). Stroke (OR, 1.82; 95% CI, 0.51-6.48; P = .35) and renal failure (OR, 1.31, 95% CI, 0.69-2.48, P = .41) were not statistically different. RFVIIa group received 4.4 (95% CI, 3.28-5.91, P = .0001) and 1.97 (95% CI, 1.18-3.30; P = .02) times more blood products volume intra- and postoperatively.
conclusionsRescue therapy with rFVIIa seems to effectively control bleeding. However, we observed an association with increased mortality, thromboembolism, and transfusion. We did not find rFVIIa association with risk of stroke or renal failure.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.